News Related to Enlicitide Decanoate

Related coverage linked through entity extraction aliases.

Oral PCSK9 Inhibitor Enlicitide Reduces LDL Cholesterol in Phase 3 Trial

Mar 05, 2026

Enlicitide decanoate demonstrated efficacy in reducing LDL cholesterol levels compared to placebo in patients with atherosclerotic cardiovascular disease history or risk, according to phase 3 CORALreef Lipids trial data.

Merck Stock Surges 46% to 52-Week High on Post-Keytruda Pipeline Strength

Feb 13, 2026

Merck stock reached a 52-week high at $122.69, rising 46.25% over 12 months and 7.4% in the past month following strong Q4 results and improved long-term pipeline outlook beyond Keytruda's 2028 patent expiration.